Picture loading failed.

Anti-TIGIT therapeutic antibody (Pre-made Tiragolumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Tiragolumab is another precision cancer immunotherapy human monoclonal antibody that targets TIGIT, an inhibitory immune checkpoint that like PD-L1 is expressed on tumor-infiltrating immune cells like T cells and NK cells.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-579-1mg 1mg 3090
GMP-Bios-ab-579-10mg 10mg 21890
GMP-Bios-ab-579-100mg 100mg 148000
GMP-Bios-ab-579-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-TIGIT therapeutic antibody (Pre-made Tiragolumab biosimilar,Whole mAb)
INN Name Tiragolumab
TargetTIGIT
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2017
Year Recommended2018
CompaniesGenentech
Conditions Approvedna
Conditions ActiveNon-small cell lung cancer;Solid tumours;Oesophageal cancer;Small cell lung cancer;Squamous cell cancer;Cervical cancer;Liver cancer;B-cell lymphoma;Breast cancer;Multiple myeloma
Conditions Discontinuedna
Development Techna